Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine

AbstractThe aim of the study was to describe automated immunoassays for autoantibodies to homocitrulline or citrulline containing telopeptides of type I and II collagen in various disease categories in an early arthritis series.Serum samples were collected from 142 patients over 16 years of age with newly diagnosed inflammatory joint disease. All samples were analyzed with an automated inhibition chemiluminescence immunoassay (CLIA) using four different peptide pairs, each consisting of a biotinylated antigen and an inhibiting peptide. Assays were performed with an IDS-iSYS analyzer. Autoantibodies binding to homocitrulline and citrulline containing C-telopeptides of type I (HTELO-I, TELO-I) and type II collagens (HTELO-II, TELO-II) were analyzed.The mean ratio of HTELO-I inhibition in seropositive and seronegative rheumatoid arthritis (RA) was 3.07 (95% CI 1.41–11.60), p=0.003, and in seropositive and seronegative undifferentiated arthritis (UA) 4.90 (1.85–14.49), p<0.001. The respective mean ratios in seropositive and seronegative RA and UA were in TELO-I 8.72 (3.68–58.01), p<0.001 and 3.13 (1.49–6.16), p=0.008, in HTELO-II 7.57 (3.18–56.60), p<0.001 and 2.97 (1.23–6.69), p=0.037, and in TELO-II 3.01 (1.30–9.51), p=0.002 and 3.64 (1.86–7.65), p=0.008. In reactive arthritis, ankylosing spondylitis, psoriatic arthritis and unspecified spondyloarthritis the inhibition levels were similar to those observed in seronegative RA or UA.Autoantibodies binding to homocitrulline or citrulline containing telopeptides of type I and II collagen did not differ significantly. They were highest among patients with seropositive disease and they differentiated seropositive and seronegative arthritis.

Download Full-text

Antibody responses to different strains of coxsackie B4 virus in patients with newly diagnosed type I diabetes mellitus or aseptic meningitis

Journal of Infection ◽

10.1016/s0163-4453(97)94143-8 ◽

1997 ◽

Vol 34 (3) ◽

pp. 205-210 ◽

Cited By ~ 13

Author(s):

G. Frisk ◽

H. Diderholm

Keyword(s):

Diabetes Mellitus ◽

Aseptic Meningitis ◽

Type I Diabetes ◽

Antibody Responses ◽

Type I Diabetes Mellitus ◽

Type I ◽

Newly Diagnosed ◽

Coxsackie B4 Virus ◽

Different Strains

Download Full-text

P006: Characterizing patients with newly-diagnosed diabetes mellitus in the emergency department: A one-year health records review

CJEM ◽

10.1017/cem.2017.208 ◽

2017 ◽

Vol 19 (S1) ◽

pp. S79

Author(s):

H. Ali Khan ◽

K. Gushulak ◽

M. Columbus ◽

I.G. Stiell ◽

J.W. Yan

Keyword(s):

Diabetic Ketoacidosis ◽

Type Ii Diabetes ◽

Type I ◽

Type Ii ◽

Newly Diagnosed ◽

Health Records ◽

The Mean ◽

One Year ◽

Diagnosed Diabetes ◽

Newly Diagnosed Diabetes

Introduction: Diabetes mellitus is an increasingly prevalent chronic condition that is usually managed in an outpatient setting. However, the emergency department (ED) plays a crucial role in the management of diabetic patients, particularly for those who are presenting with newly diagnosed diabetes. Little research has been done to characterize the population of patients presenting to the ED with hyperglycemia with no previous diagnosis of diabetes. The objective of this study was to describe the epidemiology, treatment, and outcomes of patients who were newly diagnosed with diabetes in the ED and to compare those with newly diagnosed type I versus type II diabetes. Methods: A one-year health records review of newly diagnosed diabetes patients ≥18 years presenting to one of four tertiary care EDs was conducted. All patients with a discharge diagnosis of hyperglycemia, diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome were screened, but only those who did not have a previous history of diabetes were included. Trained research personnel collected data on patient characteristics, management, disposition, and outcome. Descriptive statistics were used to summarize the data where appropriate. Results: Of 645 patients presenting with hyperglycemia in the study period, 112 (17.4%) were newly diagnosed diabetes patients. Of these patients, 30 (26.8%) were later diagnosed with type I diabetes and 82 (73.2%) were diagnosed with type II diabetes. For the newly diagnosed type I patients the mean (SD) age was 27.6 (9.9) and the mean (SD) age for type II patients was 52.4 (14.1). Of all the new onset patients, 26.8% were diagnosed with diabetic ketoacidosis. The percentage of patients diagnosed with diabetic ketoacidosis was higher in type I than type II (63.3% vs 13.4%; P<0.01). A total of 49 (43.8%) patients were admitted to the hospital, and more patients with type I were admitted compared to those with type II (66.7% vs 35.4 %; P<0.01). Conclusion: Limited research has been done to describe patients newly diagnosed with diabetes in the ED. Patients with type I were found to be more likely to present to the ED with serious symptoms requiring admission to hospital. Our findings demonstrate that the ED may have a strong potential role for improving diabetic care, by providing future opportunities for education and follow-up in the ED to reduce complications, particularly in type I.

Download Full-text

ASSESSMENT OF VITAMIN D THERAPY EFFECT ON INFLAMMATORY MARKERS IN PEDIATRIC PATIENTS WITH TYPE I DIABETIC

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2018.v11i10.28936 ◽

2018 ◽

Vol 11 (10) ◽

pp. 552 ◽

Cited By ~ 1

Author(s):

Kadhim Ali Kadhim ◽

Lubab Tarek Nafea ◽

Hayder A Fawzi ◽

Esraa Abdul-al Hameed ◽

Gaith Ali Gasim

Keyword(s):

Vitamin D ◽

Serum Calcium ◽

Vitamin D3 ◽

Pediatric Patients ◽

Serum Vitamin ◽

Type I ◽

Insulin Regimen ◽

Newly Diagnosed ◽

Daily Insulin ◽

Therapy Effect

Objective: The objective of this study is to estimate the effect of Vitamin D3 supplementation on endogenous Vitamin D3 level and inflammatory biomarkers in newly diagnosed pediatric patients.Methods: The patients were given oral Vitamin D3, and they divided into three groups: The first group (25 healthy pediatrics), the second group (25 newly diagnosed pediatric patients) treated with daily insulin regimen only, and the third group (25 newly diagnosed pediatric patients) treated with Vitamin D3 (2000 IU/day) with daily insulin regimen; all patients were treated for 90 days; and blood samples were taken at baseline and after 45 days and 90 days of starting Vitamin D3 to assess its potential effect on the levels of Vitamin D, serum calcium, serum alkaline phosphatase levels, and other inflammatory markers.Results: The results of the current study showed that serum IL-1β significantly declined in patients receiving Vitamin D3, while serum Vitamin D3, serum calcium, and interleukins-4 were significantly increased in patients receiving Vitamin D3.Conclusion: Vitamin D3 in a daily dose of 2000 IU/day for 90 days results in favorable immune response and increase of serum Vitamin D3 for pediatric new diagnosed Type 1 diabetes mellitus patients.

Download Full-text